Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
Enrico Torre,1 Giacomo M Bruno,2 Sergio Di Matteo,2 Chiara Martinotti,2 Maria Chiara Valentino,2 Luigi C Bottaro,3 Giorgio L Colombo4 1Endocrinology Diabetology and Metabolic Diseases Unit - ASL3, Genoa, Italy; 2S.A.V.E. Studi Analisi Valutazioni Economiche S.r.l., Health Economics & Outcomes Re...
Saved in:
Main Authors: | Torre E (Author), Bruno GM (Author), Di Matteo S (Author), Martinotti C (Author), Valentino MC (Author), Bottaro LC (Author), Colombo GL (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
by: Torre E, et al.
Published: (2018) -
Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
by: Torre E, et al.
Published: (2022) -
Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives
by: Torre E, et al.
Published: (2024) -
Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
by: Enrico Torre, et al.
Published: (2020) -
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023)